Covered recipient · General Payments record
CHRISTINE N CLANCY
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Gerontology
General Payments · PY2021–2024
$1,292.01
- Reported across 44 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $621.93 | 16 |
| Education | $11.29 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $145.03 | 7 |
| Amgen Inc. | $140.80 | 1 |
| Corcept Therapeutics | $138.73 | 3 |
| Medtronic, Inc. | $82.62 | 1 |
| Novo Nordisk AS | $57.37 | 2 |
| DEXCOM, INC. | $29.33 | 1 |
| CHIESI USA, INC. | $23.89 | 1 |
| Amphastar Pharmaceuticals, Inc. | $15.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $24.41 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125090266 | CMS |
| Abbott Laboratories | $24.40 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125090268 | CMS |
| Abbott Laboratories | $24.42 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125090270 | CMS |
| Abbott Laboratories | $24.71 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125090272 | CMS |
| Abbott Laboratories | $14.24 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125090274 | CMS |
| Abbott Laboratories | $24.83 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125090276 | CMS |
| Abbott Laboratories | $8.02 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125090278 | CMS |
| Amgen Inc. | $140.80 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115511834 | CMS |
| Amphastar Pharmaceuticals, Inc. | $15.45 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149951230 | CMS |
| Chiesi USA, Inc. | $23.89 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151828327 | CMS |
| Corcept Therapeutics | $101.81 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117767662 | CMS |
| Corcept Therapeutics | $11.29 | 10/30/2024 | Education | Undisputed | 01/23/2026 | 1117767738 | CMS |
| Corcept Therapeutics | $25.63 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117767702 | CMS |
| Dexcom, Inc. | $29.33 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153354780 | CMS |
| Medtronic, Inc. | $82.62 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116953728 | CMS |
| Novo Nordisk Inc | $30.56 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100327746 | CMS |
| Novo Nordisk Inc | $26.81 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100264706 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.